|
Dr. Logan is a Founder and serves as Chairman, President and CEO of Fios Therapeutics Inc. (FIOS). Immediately prior to the formation of FIOS, Dr. Logan was a management consultant to the biotechnology industry and his major projects included work on the use of stem cells in cardiac disease, development of novel anti-virals for the treatment of HIV and as an advisor to Mayo Medical Ventures. Previous to that Dr. Logan was responsible for all of the activities of Nextran, Inc., a division of Baxter Healthcare. Nextran was focused on the development of genetically modified animals for use in xenotransplantation. As part of the activities of Nextran, Dr. Logan managed the world's first FDA cleared clinical trial of genetically modified organs for the treatment of patient's in fulminant hepatic failure. Before Nextran Dr. Logan was Chief Scientific Officer of DNX Corporation, the first commercial enterprise devoted to the development of biomedical and pharmaceutical applications of transgenic animal technology. Dr. Logan started his career in the biotechnology industry as a senior scientist at American Cyanamid Corporation. He holds a BSc (Hons) and PhD in biochemistry from the University of Glasgow and did post-doctoral training at Princeton University. | 